Emcure Pharma forms subsidiary to strengthen dermatology portfolio
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
We now rank 3rd in pharmaceutical production by volume and 14th by value
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Subscribe To Our Newsletter & Stay Updated